FY2019 EPS Estimates for Becton Dickinson and Co (NYSE:BDX) Lifted by Piper Jaffray Companies

Becton Dickinson and Co (NYSE:BDX) – Analysts at Piper Jaffray Companies lifted their FY2019 earnings per share (EPS) estimates for Becton Dickinson and in a research note issued to investors on Tuesday, August 6th. Piper Jaffray Companies analyst W. Quirk now expects that the medical instruments supplier will earn $11.66 per share for the year, up from their prior forecast of $11.54. Piper Jaffray Companies has a “Overweight” rating and a $266.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q4 2019 earnings at $3.29 EPS, Q1 2020 earnings at $3.04 EPS, Q2 2020 earnings at $3.13 EPS, Q3 2020 earnings at $3.31 EPS, Q4 2020 earnings at $3.56 EPS, FY2020 earnings at $13.04 EPS and FY2021 earnings at $14.45 EPS.

Other equities research analysts have also issued reports about the company. Barclays raised Becton Dickinson and from an “equal weight” rating to an “overweight” rating and set a $266.00 price target for the company in a research report on Monday, May 13th. KeyCorp reissued an “overweight” rating and issued a $262.00 price target (down from $273.00) on shares of Becton Dickinson and in a research report on Friday, May 10th. ValuEngine lowered Becton Dickinson and from a “buy” rating to a “hold” rating in a research report on Thursday, August 1st. BMO Capital Markets lowered their price target on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating for the company in a research report on Friday, May 10th. Finally, Zacks Investment Research raised Becton Dickinson and from a “sell” rating to a “hold” rating in a research report on Monday, May 20th. Five analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Becton Dickinson and presently has an average rating of “Buy” and an average target price of $264.27.

Shares of BDX opened at $254.35 on Thursday. The company has a market cap of $66.06 billion, a PE ratio of 21.65, a P/E/G ratio of 1.81 and a beta of 1.11. The stock has a fifty day moving average price of $251.54. Becton Dickinson and has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 1.09, a quick ratio of 0.59 and a debt-to-equity ratio of 0.84.

Becton Dickinson and (NYSE:BDX) last issued its earnings results on Tuesday, August 6th. The medical instruments supplier reported $3.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.05 by $0.03. Becton Dickinson and had a return on equity of 14.78% and a net margin of 5.02%. The company had revenue of $4.35 billion for the quarter, compared to analysts’ expectations of $4.37 billion. During the same period last year, the business earned $2.91 EPS. Becton Dickinson and’s quarterly revenue was up 1.7% compared to the same quarter last year.

The business also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Investors of record on Monday, September 9th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 1.21%. The ex-dividend date is Friday, September 6th. Becton Dickinson and’s payout ratio is currently 27.97%.

In other news, EVP Simon D. Campion sold 2,903 shares of the firm’s stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $236.94, for a total transaction of $687,836.82. Following the completion of the sale, the executive vice president now directly owns 9,408 shares of the company’s stock, valued at approximately $2,229,131.52. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider James C. Lim sold 1,929 shares of the firm’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $252.01, for a total value of $486,127.29. The disclosure for this sale can be found here. Insiders sold a total of 26,229 shares of company stock valued at $6,218,565 over the last three months. 0.12% of the stock is currently owned by insiders.

Several institutional investors have recently made changes to their positions in BDX. Ronna Sue Cohen increased its position in shares of Becton Dickinson and by 24,129.0% during the 1st quarter. Ronna Sue Cohen now owns 5,734,031 shares of the medical instruments supplier’s stock valued at $5,734,000 after purchasing an additional 5,710,365 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in shares of Becton Dickinson and by 25,302.2% during the 2nd quarter. Thoroughbred Financial Services LLC now owns 990,940 shares of the medical instruments supplier’s stock valued at $99,094,000 after purchasing an additional 987,039 shares during the last quarter. FMR LLC increased its position in shares of Becton Dickinson and by 5.0% during the 1st quarter. FMR LLC now owns 17,835,000 shares of the medical instruments supplier’s stock valued at $4,453,934,000 after purchasing an additional 842,590 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Becton Dickinson and by 10.4% during the 1st quarter. JPMorgan Chase & Co. now owns 4,418,870 shares of the medical instruments supplier’s stock valued at $1,103,526,000 after purchasing an additional 416,459 shares during the last quarter. Finally, Intermede Investment Partners Ltd purchased a new stake in shares of Becton Dickinson and during the 2nd quarter valued at $76,019,000. 84.85% of the stock is owned by hedge funds and other institutional investors.

About Becton Dickinson and

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: What is dollar cost averaging (DCA)?

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.